Cryptotanshinone differentially induces cell death in ATP6V0D1-deficient pancreatic cancer cells

Abstract

Aim: Dysregulation of tumor-suppressive pathways can lead to constitutive activation of multiple oncogenic signaling cascades. Such overactivation makes cancer cells highly dependent on these pathways, creating potential therapeutic vulnerabilities. Based on our previous findings and current data, genetic knockout of ATPase H⁺ transporting V0 subunit D1 (ATP6V0D1) - a key mediator of alkaliptosis - induces hyperactivation of oncogenic pathways, including signal transducer and activator of transcription 3 (STAT3)-mediated lysosomal pH regulation and AKT serine/threonine kinase (AKT) signaling. It also alters cellular responses to cryptotanshinone therapy. This study aimed to investigate how ATP6V0D1 deficiency reshapes oncogenic signaling networks and cellular heterogeneity in pancreatic ductal adenocarcinoma (PDAC), while evaluating therapeutic strategies that exploit alkaliptosis-related vulnerabilities.

Methods:ATP6V0D1-deficient SW1990 and MIAPaCa2 cells were generated via gene knockdown. Cell viability and death following various treatments were assessed using CCK-8 and propidium iodide assays. Transcriptomic analysis was conducted to identify feedback signaling pathways, while Western blotting was used to measure expression of signaling proteins. Macropinocytosis was evaluated by TRITC-dextran uptake. Additionally, The Cancer Dependency Map (DepMap) database was analyzed to explore background differences between SW1990 and MIAPaCa2 cells.

Results:ATP6V0D1 deletion led to overactivation of STAT3-mediated lysosomal pH regulation and AKT signaling; inhibition of these pathways restored alkaliptosis. Notably, cryptotanshinone selectively induced cell death in ATP6V0D1-deficient MIAPaCa2 cells but not SW1990 cells. Resistance in SW1990 cells was mediated by FGFR2 upregulation, which was reversed upon FGFR2 inhibition.

Conclusion:ATP6V0D1 deficiency drives PDAC progression via dual mechanisms: compensatory oncogenic signaling (STAT3/AKT) and FGFR2-mediated cellular heterogeneity. While targeting these pathways may offer therapeutic potential, tumor heterogeneity remains a major clinical challenge.

Keywords

ATP6V0D1 / cryptotanshinone / cell death / tumor heterogeneity

References

[1] Laplane L.The evolutionary theory of cancer: challenges and potential solutions.Nat Rev Cancer2024;24:718-33 PMCID:PMC11627115

[2] Lee HJ,Cao Y,Kim HJ.Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells.Cancer Cell2014;26:207-21

[3] Zeng H,Jin N.Feedback activation of leukemia inhibitory factor receptor limits response to histone deacetylase inhibitors in breast cancer.Cancer Cell2016;30:459-73

[4] Wu Q,Shi L.EGFR inhibition potentiates FGFR inhibitor therapy and overcomes resistance in FGFR2 fusion-positive cholangiocarcinoma.Cancer Discov2022;12:1378-95 PMCID:PMC9064956

[5] Zhao M,Liu Y.miR-3188 regulates nasopharyngeal carcinoma proliferation and chemosensitivity through a FOXO1-modulated positive feedback loop with mTOR-p-PI3K/AKT-c-JUN.Nat Commun2016;7:11309 PMCID:PMC4842991

[6] Adachi Y,Hirade K.Scribble mis-localization induces adaptive resistance to KRAS G12C inhibitors through feedback activation of MAPK signaling mediated by YAP-induced MRAS.Nat Cancer2023;4:829-43

[7] Ngoi NYL,Torrado C,Durocher D.Synthetic lethal strategies for the development of cancer therapeutics.Nat Rev Clin Oncol2025;22:46-64

[8] Chen F,Kang R,Liu J.ATP6V0D1 promotes alkaliptosis by blocking STAT3-mediated lysosomal pH homeostasis.Cell Rep2023;42:111911

[9] Song X,Xie Y.JTC801 induces pH-dependent death specifically in cancer cells and slows growth of tumors in mice.Gastroenterology2018;154:1480-93 PMCID:PMC5880694

[10] Chen F,Li C,Tang D.CYP51A1 drives resistance to pH-dependent cell death in pancreatic cancer.Nat Commun2025;16:2278 PMCID:PMC11889236

[11] Li C,Liu C.AGER-dependent macropinocytosis drives resistance to KRAS-G12D-targeted therapy in advanced pancreatic cancer.Sci Transl Med2025;17:eadp4986

[12] Pechincha C,Kalis R.Lysosomal enzyme trafficking factor LYSET enables nutritional usage of extracellular proteins.Science2022;378:eabn5637

[13] Commisso C,Soydaner-Azeloglu RG.Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells.Nature2013;497:633-7 PMCID:PMC3810415

[14] Palm W,Wright K,Tuveson DA.The utilization of extracellular proteins as nutrients is suppressed by mTORC1.Cell2015;162:259-70 PMCID:PMC4506698

[15] Albrecht LV,Bui MH.GSK3 inhibits macropinocytosis and lysosomal activity through the Wnt destruction complex machinery.Cell Rep2020;32:107973 PMCID:PMC7666578

[16] Katoh M,Brandi G,Wainberg ZA.FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions.Nat Rev Clin Oncol2024;21:312-29

[17] Hou Y,Zhao L.A small molecule cryptotanshinone induces non-enzymatic NQO1-dependent necrosis in cancer cells through the JNK1/2/Iron/PARP/calcium pathway.Acta Pharm Sin B2025;15:991-1006 PMCID:PMC11959885

[18] Kim JH,Kwon TR.Cryptotanshinone enhances TNF-α-induced apoptosis in chronic myeloid leukemia KBM-5 cells.Apoptosis2011;16:696-707

[19] Xu Z,Zhu Y.Cryptotanshinone induces ROS-dependent autophagy in multidrug-resistant colon cancer cells.Chem Biol Interact2017;273:48-55

[20] Cheng C,Mannan R.Targeting PIKfyve-driven lipid metabolism in pancreatic cancer.Nature2025;642:776-84 PMCID:PMC12176661

[21] Smith SJ,Lingeman RG.Therapeutic targeting of oncogene-induced transcription-replication conflicts in pancreatic ductal adenocarcinoma.Gastroenterology2025;169:600-14.e11

[22] Herencia-Ropero A,Staniszewska AD.The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models.Genome Med2024;16:107 PMCID:PMC11348616

[23] Ramakrishnan N,Aubuchon LN.Nucleolytic processing of abasic sites underlies PARP inhibitor hypersensitivity in ALC1-deficient BRCA mutant cancer cells.Nat Commun2024;15:6343 PMCID:PMC11283519

[24] Cobo I,Alishala M.Particle uptake by macrophages triggers bifurcated transcriptional pathways that differentially regulate inflammation and lysosomal gene expression.Immunity2025;58:826-42.e8 PMCID:PMC12093573

[25] Wang F,Boya P.Lysosomal membrane permeabilization and cell death.Traffic2018;19:918-31

[26] Cañeque T,Müller S.Activation of lysosomal iron triggers ferroptosis in cancer.Nature2025;642:492-500 PMCID:PMC12158755

[27] Zhang HL,Ye ZP.TRPML1 triggers ferroptosis defense and is a potential therapeutic target in AKT-hyperactivated cancer.Sci Transl Med2024;16:eadk0330